ホームSGEN • BMV
add
Seagen
市場ニュース
財務情報
損益計算書
収益
純利益
(USD) | 2023年9月info | 前年比変化率 |
---|---|---|
収益 | 6.49億 | 27.11% |
営業費用 | 2.63億 | 24.86% |
純利益 | -2.16億 | -13.09% |
純利益率 | -33.27 | 11.02% |
1 株当たりの収益 | -1.15 | -11.65% |
EBITDA | -2.09億 | -19.47% |
実効税率 | 0.26% | — |
貸借対照表
総資産
負債総額
(USD) | 2023年9月info | 前年比変化率 |
---|---|---|
現金および短期投資 | 12.37億 | -29.86% |
総資産 | 36.34億 | 0.42% |
負債総額 | 10.84億 | 35.94% |
純資産 | 25.50億 | — |
発行済み株式 | 1.89億 | — |
帳簿価格 | 274.52 | — |
総資産利益率 | -16.01% | — |
資本利益率 | -21.12% | — |
キャッシュ フロー
現金の純増減額
(USD) | 2023年9月info | 前年比変化率 |
---|---|---|
純利益 | -2.16億 | -13.09% |
営業キャッシュ フロー | -3582.30万 | 58.21% |
投資キャッシュ フロー | 1.42億 | 119.31% |
財務キャッシュ フロー | 1552.20万 | -15.59% |
現金の純増減額 | 1.20億 | 1,958.05% |
フリー キャッシュ フロー | 7152.48万 | 1,141.10% |
概要
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
設立
1997/07/15
本社所在地
ウェブサイト
従業員数
3,256